RESEARCH LETTER

Tuberculosis through the rose tinted spectacles of the EBUS endoscopist: be aware of the bias

I read with interest the article on the utility of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in tuberculous intrathoracic lymphadenopathy by Navani et al.1

EBUS-TBNA has been validated for the assessment of mediastinal nodes in lung cancer2 and to obtain a diagnosis in (presumed) centrally located lung cancer3 or sarcoidosis.4 In addition to a recent report,5 the study by Navani et al adds to the evidence for the use of EBUS-TBNA in cases of presumed tuberculous lymphadenitis. A sensitivity of 94% is reported, which might be too optimistic.

First, patients were selected in a peculiar way. The authors reviewed the files of all EBUS endoscopies and retrospectively selected those cases in which tuberculosis was finally found. Unfortunately, there is no information on how the patients were selected beforehand. The reported figure gives an indication of the sensitivity of EBUS in this particular setting; however, it does not give an answer to the more relevant question about the sensitivity of EBUS-TBNA for all cases in whom tuberculous lymphadenitis is suspected. There were potentially many patients with tuberculous intrathoracic lymphadenitis who were not sent for EBUS.

Second, the use of assessment tools (ie, EBUS) only in patients having the condition leads to an overestimation of sensitivity. Since there is no remedy for the overestimation in this series, the results should be interpreted with caution.

Finally, three of the five pathology grades are regarded as compatible with tuberculosis. Two of these, epithelioid granulomas without caseation and necrosis are primarily compatible with sarcoidosis and cancer rather than tuberculosis,5 despite suggestive symptomatology or an (undefined) response to medication. A more conservative analysis combining strict pathological and microbiological criteria would be informative.

Therefore, it might be appropriate to say that for tuberculous lymphadenitis, the sensitivity of EBUS is at the most 94%. Although I recognise the importance of EBUS, my reflections should serve as a reminder to doctors to exercise caution when their diagnosis of tuberculosis is based on the idea that the sensitivity of EBUS is 94% and that a negative EBUS excludes the disease.

Kurt Tournoy

Correspondence to Dr Kurt Tournoy, Ghent University Hospital, Department of Respiratory Medicine, Building 7 K12 IE, De Pintelaan 185, Ghent 9000, Belgium; kurt.tournoy@ugent.be

Competing interests None.
Contributors KT is the sole contributor.
Provenance and peer review Not commissioned; internally peer reviewed.
Accepted 11 October 2011
Published Online First 18 November 2011
doi:10.1136/thoraxjnl-2011-201149

REFERENCES

CORRESPONDENCE

Authors’ response

We thank Dr Young for his comments on the recent UKLS position statement.1 We are aware of the current studies on chronic obstructive pulmonary disease (COPD) and lung cancer. However, there is no validated lung cancer risk model in the UK which currently incorporates dynamic lung volumes that could be used in the UKLS trial. All the recruited individuals will have spirometry at the time that they are recruited into the UKLS trial, thus data will be available for developing the Liverpool Lung Project risk model.2 3 We do not wish to focus on COPD risk groups for the pilot UKLS trial.

Smoking is the over-riding risk factor in lung cancer. Our measurements will provide further information concerning the potential for COPD as a useful factor in selecting populations that may benefit from screening. We do not have population-based spirometry in the UK to screen populations and there is an issue over the diagnostic crossover between COPD and asthma.

The search for molecular biomarkers and susceptibility genes, which may be used in early detection programmes, has proved challenging; although there are a number of promising candidates,4–7 none, to date, has been validated to a level where they can be used in an early lung cancer clinical trial.

John Field,1 David Baldwin,2 Kate Brain,3 Anand Devaara,4 Tim Eisen,5 Stephen W Duffy,6 David M Hansell7, Keith Kerr,8 Richard Page,9 Mahash Parmar,10 David Weller,11 David Whynes,12 Paula Williamson13

1 Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre, Liverpool, UK; 2City Campus, Nottingham University Hospitals, Nottingham, UK; 3Institute of Medical Genetics, Cardiff University, Cardiff, UK; 4Department of Radiology, St George’s Hospital London, London, UK; 5Department of Oncology, University of Cambridge, Cambridge, UK; 6Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, London, UK; 7Department of Radiology, Royal Brompton Hospital, London, UK; 8Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, UK; 9Department of Surgery, Liverpool Heart & Chest Hospital, Liverpool, UK; 10Medical Statistics and Epidemiology, University College London, London, UK; 11Clinical Sciences and Community Health, Division of Community Health Sciences, University of Edinburgh, Edinburgh, UK; 12School of Economics, University of Nottingham, Nottingham, UK; 13Department of Medical Statistics, University of Liverpool, Liverpool, UK

Correspondence to Professor John Field, Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre, Roy Castle Building, 200 London Road, London L3 9TA, UK; j.k.field@lv.ac.uk

Funding National Institute for Health Research Health Technology Assessment.

Patient consent Obtained.

Ethics approval The UKLS trial has received Ethical Approval

Provenance and peer review Not commissioned; internally peer reviewed.

Accepted 20 July 2011
Published Online First 13 September 2011
doi:10.1136/thoraxjnl-2011-200822

REFERENCES

CT screening for lung cancer

We read with interest the recent opinion piece by Field et al8 outlining plans for a CT screening trial in the United Kingdom (the
UK Lung Screen (UKLS) following the results of the National Lung Cancer Screening Trial. We agree that cost-effectiveness and defining who would most likely benefit from CT screening remain key issues to be resolved before CT screening can be offered routinely in clinical practice.²

First, cost-effectiveness is most likely to be achieved through optimising the risk assessment of those potentially eligible for CT screening¹ and maximising the number of cancers identified for each scan done. While historical data may assist in this risk assessment,² it is possible that biomarkers are required to better stratify this risk. In this regard, we and others have shown that a reduced forced expiratory volume in one second (FEV1) is the single most important risk factor (and biomarker) for lung cancer susceptibility and is present in up to 80% of those diagnosed with lung cancer.³ We hypothesise that targeting those smokers with mildly or moderately reduced FEV1 may help maximise picking up of ‘treatable’ lung cancer.¹ Such an approach was reported in a small community-based study where lung cancer was detected in 6% of those who underwent baseline CT screening,² much greater (by over threefold) than that reported by the National Lung Cancer Screening Trial and estimated in the UKLS (1–2%).² In the absence of abnormal lung function, other biomarkers such as gene-based risk stratification⁵ might have utility in identifying those at the greatest risk of lung cancer. We note that although neither lung function nor DNA sampling contributes to the Liverpool Lung Cancer Risk Prediction Model,² all UKLS participants have these taken.²

Second, apart from optimising entry into a CT-based screening programme, cost-effectiveness might also be improved by limiting subsequent CT screening according to the risk profile. In this regard, we hypothesise that smokers with normal lung function, no evidence of emphysema on baseline CT scan and/or ‘low gene-based risk’⁵ might not require yearly scanning. Such a group might defer scanning (or increase the scanning interval), much like colonoscopy for bowel cancer screening is individualised according to the risk level.¹ Both these hypotheses could be examined in the UKLS where the ‘single screen’ design and DNA sampling enable a gene-based risk model to be examined with respect to predictability and survival (figure 1). We conclude that optimisation of patient selection and scan interval, through biomarker-based risk stratification, may help improve the cost-effectiveness of CT screening.

Robert P Young, Raewyn J Hopkins
Schools of Biological Sciences and Health Sciences,
University of Auckland, Auckland, New Zealand

Correspondence to Dr Robert P Young, Director,
Respiratory Genetics Group, Schools of Biological Sciences and Health Sciences, University of Auckland,
PO Box 26161, Epsom 1344, Auckland, New Zealand;
roberty@adhb.govt.nz

Funding RPY, and his research, is supported by grants from the University of Auckland, Health Research Council of New Zealand and Synergens Bio Sciences Ltd.

Competing interests None.

Contributors RPY wrote and researched the letter. RJH wrote, edited and researched the letter.

Provenance and peer review Not commissioned; internally peer reviewed.

Accepted 22 August 2011
Published Online First 13 September 2011

Figure 1 Proposed study design to assess cost-effectiveness in the UK Lung Screen using spirometry and gene-based risk stratification to optimise lung cancer detection rate. LLP, Liverpool Lung Project model.²

CT screening for lung cancer: so near, yet so far

The UK Lung Screen team in their positional statement outlined the issues to be explored by the trial on CT screening for lung cancer. Although it seems to be a large, well-planned study, we believe that there are some short-comings in this study that may undermine its significance. There are several other aspects of CT screening that need to be investigated in order to determine the suitability of the screening and thus guide a national programme. The additional investigation areas may include:

1. Studying the number of unnecessary lung biopsies, invasive procedures and surgeries due to cancer screening and the morbidity and mortality caused by these procedures.
2. The risk of development of radiation-induced malignancy, both in patients undergoing routine yearly screening and in those subjected to serial CT scans for suspicious lesions. Some studies have shown significant risk of development of radiation-induced malignancies.²
3. Smoking abstinence behaviour in people undergoing screening. Concerns have been raised regarding smokers having a negative result on CT screening believing that they can continue smoking without any increased risk of dying from lung cancer.³ Such behaviour can expose them to other potentially fatal smoking-related diseases like chronic obstructive pulmonary disease and other malignancies.
4. Emotional and psychological effects of false positive results, which can significantly impair the life of the individual.

REFERENCES

DOI: 10.1136/thoraxjnl-2011-200766

doi:10.1136/thoraxjnl-2011-200766

CT screening for lung cancer

Robert P Young and Raewyn J Hopkins

Thorax 2012 67: 650-651 originally published online September 13, 2011
doi: 10.1136/thoraxjnl-2011-200766

Updated information and services can be found at:
http://thorax.bmj.com/content/67/7/650.3

These include:

References
This article cites 5 articles, 4 of which you can access for free at:
http://thorax.bmj.com/content/67/7/650.3#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/